Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Staphylococcal Infections 1Sepsis 1Infections 1Bacteremia 1

Interventions

Anti-Bacterial Agents 2ziprasidone 1telavancin 1soybean oil, phospholipid emulsion 1drotrecogin alfa activated 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tranexamic Acid 1Tobramycin 1Spironolactone 1Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization 1Simvastatin 1Sevelamer 1Saline Solution 1Rocuronium 1Povidone-Iodine 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Multiplex Polymerase Chain Reaction 1Molindone 1Methylprednisolone 1Methods 1Meropenem 1Massage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sepsis × telavancin × Clear all
NCT01321879 2019-12-27

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 6 charts

Infections, Staphylococcal Infections, Bacteremia, Sepsis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡